Evaxion Biotech AS (EVAX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $25.27M
Last updated: Nov 17, 2026 at 4:10 PM ET
Evaxion Biotech AS (EVAX) Statistics
Evaxion Biotech AS (EVAX) has a market cap of $25.27M and an enterprise value of $16.58M. Its share count is down 62.27% from a year earlier. Revenue grew 127.84% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 34.38% below the market cap, as cash exceeds debt.
| Market Cap | $25.27M |
|---|---|
| Enterprise Value | $16.58M |
| Latest price (Nov 17, 2026) | $2.78 |
Key Dates
The next earnings report is set for Nov 19, 2026, before the open.
| Next Earnings Date | Nov 19, 2026, before the open |
|---|---|
| Last Earnings Date | Aug 13, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.2x and 0.1x. Its year-end P/S ranged from 0.7x to 321.0x from 2023 to 2025.
| P/S Ratio | 0.2x |
|---|---|
| P/B Ratio | 0.1x |
Enterprise Valuation
Counting debt and cash, the company is valued at 0.4x free cash flow.
| EV / Sales | 2.2x |
|---|---|
| EV / FCF | 0.4x |
Price Statistics
The stock is down 49.08% over 52 weeks and trades 10.61% below its 50-day average.
| Beta (1Y) | 0.45 |
|---|---|
| 52-Week Change | -49.08% |
| 1-Month Change | -16.52% |
| 3-Month Change | -11.75% |
| 6-Month Change | -30.15% |
| 5-Year Change | -99.23% |
| Total Return (1Y) | -49.08% |
| Total Return (3Y CAGR) | -57.60% |
| Total Return (5Y CAGR) | -60.05% |
| Return vs SPY (1Y) | -58.71% |
| Max Drawdown (1Y) | -58.67% |
| Max Drawdown (3Y) | -97.55% |
| Sharpe Ratio (1Y) | -0.81 |
| Correlation with SPY (1Y) | 0.08 |
| 50-Day Average | $3.11 |
| 200-Day Average | $3.43 |
| 52-Week Range | $2.65 to $6.92 |
| RSI (14 Days) | 43.1 |
| Average Volume (20 Days) | 89.97K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 5.06x current liabilities, and total debt is 0.56x shareholder equity.
| Current Ratio | 5.06x |
|---|---|
| Quick Ratio | 5.06x |
| Debt / Equity | 0.56x |
| Interest Coverage | -4.40x |
Returns and Efficiency
Return on invested capital is -79.46% and return on equity is -90.79% over the last 12 months.
| Return on Equity (ROE) | -90.79% |
|---|---|
| Return on Assets (ROA) | -44.65% |
| Return on Invested Capital (ROIC) | -79.46% |
| Asset Turnover | 0.36x |
| Receivables Turnover | 8.26x |
Scores
EVAX has an Altman Z-Score of -10.62, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -10.62 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $7.51M over the last 12 months.
| Revenue | $7.51M |
|---|---|
| Revenue Growth (YoY) | +127.84% |
| Operating Income | -$8.69M |
| Pretax Income | -$9.59M |
| Net Income | -$8.65M |
| Reported EPS (TTM) | -$0.51 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 49.17% of the $19.38M in total assets.
| Cash and Equivalents | $14.00M |
|---|---|
| Total Debt | $5.31M |
| Net Cash | $8.69M |
| Working Capital | $12.72M |
| Shareholder Equity | $9.53M |
| Total Assets | $19.38M |
| Total Liabilities | $9.85M |
Balance sheet as of Jun 30, 2026.
Cash Flow
| Capital Expenditures | $11.03K |
|---|---|
| FCF Per Share | -$1.91 |
Trailing 12 months through Jun 30, 2026.
Margins
The operating margin is -115.64%.
| Operating Margin | -115.64% |
|---|---|
| Pretax Margin | -127.67% |
| Net Margin | -115.15% |
Dividends and Yields
EVAX does not pay a dividend. Its free cash flow yield is -1515.96%.
| FCF Yield | -1515.96% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-5 reverse split on Jan 14, 2025.
| Last Split Date | Jan 14, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:5 |
Peer Position
Against 3 similar companies, EVAX has the lowest P/S.
P/S RatioPeer median 2.1x
ROICPeer median -102.82%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| P/S Ratio | 0.2x vs 2.1x median |
|---|---|
| ROIC | -79.46% vs -102.82% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +127.84% vs -100.00% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About EVAX
What is EVAX's market cap?
Evaxion Biotech AS has a market cap of $25.27M. Its enterprise value, which adds debt and subtracts cash, is $16.58M.
How many shares of EVAX are outstanding?
Evaxion Biotech AS has 417.01K shares outstanding. The count is down 62.27% from a year earlier.
Does EVAX pay a dividend?
No. Evaxion Biotech AS does not pay a dividend.
How much debt does EVAX have?
Evaxion Biotech AS has $5.31M of total debt and $14.00M of cash and equivalents, a net cash position of $8.69M.
EVAX pages: Overview, Charting, Earnings, Forecast, Statistics, Valuation, Competitors